<DOC>
	<DOC>NCT02804204</DOC>
	<brief_summary>Multicenter, prospective, observational study for evaluating if circulant rheumatoid factor, cyclic citrullinated anti-peptide anti-bodies and albumin can be used as potential predictors in the response to the treatment with anti-TNF in patients with rheumatoid arthritis after 24 weeks of treatment.</brief_summary>
	<brief_title>Serum Biomarkers Analysis in Patients With AR Treated With Anti-TMF</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Both genders Over 18 years old Diagnosis of rheumatoid arthritis according to ACR criteria Patients that initiate treatment with antiTNF drugs according to clinical practice, both in na√Øve antiTNF patients and patients after first antiTNF failure Patients able to follow the protocol requirements Patients that signed the informed consent Patients with known hypersensitivity to investigational products Patients with tuberculosis, or severe infections like sepsis or opportunistic infections Patients with moderate/severe cardiac insufficiency (NHYA classification Class III/IV) Patients that according to the investigator criteria can not participate in the study or complete the study questionnaires Pregnant or fertile woman that does not use a contraception method</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>